OMER

Omeros Corporation is a clinical-stage biopharmaceutical company. The Company is focused on discovering, developing, and commercializing first-in-class small-molecule and protein therapeutics for both large-market and orphan diseases, with a particular emphasis on complement-mediated diseases, cancers, and addictive or compulsive disorders. The Company's lead MASP-2 inhibitor, narsoplimab, targets the lectin pathway of complement and is the subject of a biologics license application pending before the FDA for the treatment of hematopoietic stem cell transplant-associated thrombotic microangiopathy. Its long-acting MASP-2 inhibitor, OMS1029, is in phase I single- and multiple-ascending-dose clinical studies. Its lead phosphodiesterase 7 (PDE7) inhibitor, OMS527, is in clinical development for the treatment of cocaine use disorders. The Company also has preclinical programs, including an oncology platform for the development of novel therapeutics.

Wall Street analysts forecast OMER stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for OMER is 13.11 USD with a low forecast of 6.22 USD and a high forecast of 20.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

Omeros Corp revenue for the last quarter amounts to 0.00 USD, decreased % YoY.

Omeros Corp. EPS for the last quarter amounts to -0.47 USD, decreased -16.07 % YoY.

Omeros Corp (OMER) has 202 emplpoyees as of December 16 2025.

Today OMER has the market capitalization of 652.28M USD.